Abstract
Anti-hepatitis B (HBs) antibody persistence and hepatitis B challenge were evaluated at 6 years of age following vaccination of fully liquid DTaP-IPV-HB-PRP~T or reconstituted DTaP-IPV-HB//PRP~T at 3, 5, 11-12 months of age. At 6 years, 53.8% and 73.5% had seroprotective anti-HBs antibodies (≥10 mIU/mL), increasing to 96.7% and 95.9% postchallenge, confirming a strong anamnestic response in primed vaccinees.
Publication types
-
Clinical Trial, Phase IV
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Child
-
Diphtheria-Tetanus-Pertussis Vaccine / administration & dosage
-
Diphtheria-Tetanus-Pertussis Vaccine / adverse effects
-
Diphtheria-Tetanus-Pertussis Vaccine / immunology*
-
Female
-
Haemophilus Vaccines / administration & dosage
-
Haemophilus Vaccines / adverse effects
-
Haemophilus Vaccines / immunology*
-
Hepatitis B Antibodies / blood*
-
Hepatitis B Vaccines / administration & dosage
-
Hepatitis B Vaccines / adverse effects
-
Hepatitis B Vaccines / immunology*
-
Humans
-
Immunization Schedule
-
Immunologic Memory / immunology*
-
Male
-
Poliovirus Vaccine, Inactivated / administration & dosage
-
Poliovirus Vaccine, Inactivated / adverse effects
-
Poliovirus Vaccine, Inactivated / immunology*
-
Vaccines, Combined / administration & dosage
-
Vaccines, Combined / adverse effects
-
Vaccines, Combined / immunology
Substances
-
DTaP-IPV-HB-PRP-T vaccine
-
Diphtheria-Tetanus-Pertussis Vaccine
-
Haemophilus Vaccines
-
Hepatitis B Antibodies
-
Hepatitis B Vaccines
-
Poliovirus Vaccine, Inactivated
-
Vaccines, Combined